Azitra (AZTR) said Wednesday that it has dosed the first patient in a phase 1b clinical study of its lead drug candidate, ATR-12, for the potential treatment of Netherton syndrome, a rare genetic skin disorder.
The company said the trial will include about 12 adult patients, who will receive twice-daily treatments over 14 days. The study's primary focus is on safety and tolerability, with efficacy and biomarker assessments as secondary and exploratory goals, the company said.
Azitra said it plans to release interim safety data early next year and full results in the second half.
Price: 0.6870, Change: -0.02, Percent Change: -2.55
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments